echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Blocking PD-1 can alleviate adrenocortical cancer

    Blocking PD-1 can alleviate adrenocortical cancer

    • Last Update: 2019-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Adrenocortical carcinoma (ACC) is a rare invasive cancer with limited treatment Recently, researchers from New York cancer hospital and other research institutions published an article in Journal of Clinical Oncology, and found that blocking PD-1 can alleviate adrenocortical cancer In this study, 39 patients with advanced ACC were enrolled, and their clinical activity was evaluated after treatment with 200mg paimmumab (PD-1 inhibitor) once every 3 weeks The primary end point was the objective response rate The validity is related to the expression of tumor programmed death ligand 1, microsatellite and / or mismatch repair defects, and somatic and germ cell genomes The median follow-up time was 17.8 months The objective remission rate was 23% (9 cases) and the disease control rate was 52% (16 cases) Two of the 6 patients with MSI-H / mmr-d tumor responded The other 7 patients with objective response were all microsatellite stable The median progression free survival was 2.1 months, and the median overall survival was 24.9 months Five patients had grade 3 or 4 side effects related to treatment The expression of tumor programmed death ligand 1 and MSI-H / mmr-d status were not related to the objective response rate This study found that pemumab can alleviate the MSI-H / mmr-d tumor in acc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.